{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"Tumor response was assessed using the revised criteria of Cheson (Cheson 2007).Tumor assessments were done using conventional radiographic methods, e.g. CT or CT/PET.","groups":[{"description":"PTCL patients will receive 1000 mg/m2 of PXD101 IV\n\nbelinostat: 1000 mg/m2 for 5 days every 21 days; IV","id":"OG000","title":"PTCL (ITT Population)"}],"paramType":"NUMBER","populationDescription":"Primary efficacy analysis is based on the ITT analysis set, where the OR are calculated, and the proportion ± 80% CI (confidence interval) specified by Koyama \\& Chen (2008) are presented","reportingStatus":"POSTED","timeFrame":"throughout the study, or for a maximum of 2 years","title":"Objective Response Rate in Patients With Recurrent or Refractory Peripheral T-cell Lymphoma (PTCL))","type":"PRIMARY","unitOfMeasure":"percentage of patients with OR"}